Rae is a 27-year-old cisgender woman who presents to your clinic to discuss birth control options. She has been sexually active with men only in the past, and she has had two sexual partners in the past three months. She denies intimate partner violence but does not feel comfortable insisting on condom use. Rae was treated three months ago for urogenital gonorrhea after a prior partner was diagnosed and treated. Her rapid HIV test at that time was negative but she does not know her current partner’s HIV status. After agreeing on injectable contraception, you recommend serologic tests for HIV and syphilis, as well as vaginal and oral screening for gonorrhea and chlamydia based on her sexual practices. Two days later, the oral nucleic acid amplification test (NAAT) returns positive for Chlamydia trachomatis. All other tests are normal. Which of the following is most appropriate? Choose: Abstain from sex for 3 days after completing therapy as well as treatment of sexual partner Azithromycin 1 g orally once Pre-exposure prophylaxis (PrEP) with emtricitabine/tenofovir alafenamide (FTC/TAF) Testing and treatment of her sexual partner